Geneva, Switzerland, 20 June 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved with a very large majority all of the proposals of the board of directors at its 2019 Annual General Meeting (AGM).

At the AGM, Addex shareholders approved the 2018 annual report, the 2018 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote). All motions regarding the compensation of the board of directors and the executive management were also approved. In addition, discharge was granted to the members of the board of directors and the executive management for their activities during the business year 2018.

Addex shareholders also apporoved the amendment of the articles of association concerning the authorized and the conditional share capital of the company.

Dr. Vincent Lawton was re-elected as member and chairman of the board of directors and member of the compensation committee; Dr. Ray Hill was re-elected as member of the board of directors and member of the compensation committee and  Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn and Dr. Isaac Manke were re-elected as members of the board of directors.

PricewaterhouseCoopers SA, Geneva, were re-elected as the auditors for the 2019 business year and Robert P. Briner, attorney-at-law was re-elected as the independent voting rights representative until the 2020 Annual General Meeting.

The detailed agenda can be found on Addex’s website at www.addextherapeutics.com/en/news-and-events/events/.

About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex' allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline has been generated from this pioneering allosteric modulator drug discovery platform. Addex' lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed by Janssen Pharmaceuticals, Inc for epilepsy. In addition, Addex’ GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Discovery programs include, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, mGlu3 PAM and TrkB PAM.

Press Contacts:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 61
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
+44 (0)20 7318 2955
msinclair@halsin.com


Disclaimer / Forward-looking statements
: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.